| Measure Type | High Priority Measure? | Collection Type(s) |
|---|---|---|
| Process | yes | eCQM, MIPS CQM |
Measure Description
Percentage of patients 65 years of age and older who were ordered at least two high-risk medications from the same drug class
Stay up to date with the latest news regarding MACRA and MIPS.
Instructions
This measure is to be submitted a minimum of once per performance period for patients seen during the performance period. There is no diagnosis associated with this measure. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.
The measure reflects potentially inappropriate medication use in older adults, both for medications where any use is inappropriate and for medications where use under all but specific indications is potentially inappropriate.
This measure will be calculated with 2 performance rates:
1. Percentage of patients 65 years of age and older who were ordered at least two high-risk medications from the same drug class.
2. Percentage of patients 65 years of age and older who were ordered at least two high-risk medications from the same drug class, except for appropriate diagnoses.
For accountability reporting in the CMS MIPS program, the rate for submission criteria 1 is used for performance.
NOTE: Patient encounters for this measure conducted via telehealth (e.g., encounters coded with GQ, GT, 95, or POS 02 modifiers) are allowable.
Measure Submission Type:
Measure data may be submitted by individual MIPS eligible clinicians, groups, or third party intermediaries. The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.
Denominator
SUBMISSION CRITERIA 1: PERCENTAGE OF PATIENTS 65 YEARS OF AGE AND OLDER WHO WERE ORDERED AT LEAST TWO HIGH-RISK MEDICATIONS FROM THE SAME DRUG CLASS
DENOMINATOR (SUBMISSION CRITERIA 1):
Patients 65 years and older who had a visit during the measurement period
Denominator Criteria:
Patients aged ≥ 65 years on date of encounter
AND
Patient encounter during performance period (CPT or HCPCS): 92002, 92004, 92012, 92014, 99202, 99203, 99204, 99205,99212, 99213, 99214, 99215, 99304, 99305, 99306, 99307, 99308, 99309, 99310, 99315, 99316, 99318, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 99337, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, 99385*, 99386*, 99387*, 99395*, 99396*, 99397*, G0438, G0439
AND NOT
DENOMINATOR EXCLUSION:
Patients who use hospice services any time during the measurement period: G9741
OR
Patients receiving palliative care during the measurement period: G0034
-OR-
SUBMISSION CRITERIA 2: PERCENTAGE OF PATIENTS 65 YEARS OF AGE AND OLDER WHO WERE ORDERED AT LEAST TWO HIGH-RISK MEDICATIONS FROM THE SAME DRUG CLASS, EXCEPT FOR APPROPRIATE DIAGNOSES
DENOMINATOR (SUBMISSION CRITERIA 2):
Patients 65 years and older who had a visit during the measurement period
Denominator Criteria:
Patients aged ≥ 65 years on date of encounter
AND
Patient encounter during performance period (CPT or HCPCS): 92002, 92004, 92012, 92014, 99202, 99203, 99204, 99205,99212, 99213, 99214, 99215, 99304, 99305, 99306, 99307, 99308, 99309, 99310, 99315, 99316, 99318, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 99337, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, 99385*, 99386*, 99387*, 99395*, 99396*, 99397*, G0438, G0439
AND NOT
DENOMINATOR EXCLUSIONS:
Patients who use hospice services any time during the measurement period: G9741
OR
Patients receiving palliative care during the measurement period: G0034
Numerator
NUMERATOR (SUBMISSION CRITERIA 1):
Patients ordered at least two high-risk medications from the same drug class during the measurement year.
Definitions:
The intent of the measure is to assess if the eligible clinician ordered high-risk medication(s). The intent of the numerator is to assess if the patient has either been ordered:
• At least two high-risk medications from the same drug class (grouped by row) in Table 1 on different dates of service, or
• At least two high-risk medications from the same drug class (grouped by row) in Table 2 on different dates of service, where the sum of days supply exceeds 90 days
If the patient had a high-risk medication previously prescribed by another provider, they would not be counted towards the numerator unless the submitting provider also ordered a high-risk medication for them from the same drug class.
Cumulative Medication Duration – an individual’s total number of medication days over a specific period; the period counts multiple prescriptions with gaps in between, but does not count the gaps during which a medication was not dispensed.
To determine the “cumulative medication duration”, determine first the number of the Medication Days for each prescription in the period: the number of doses divided by the dose frequency per day. Then add the Medication Days for each prescription without counting any days between the prescriptions.
For example, there is an original prescription for 30 days with 2 refills for thirty days each. After a gap of 3 months, the medication was ordered again for 60 days with 1 refill for 60 days. The “cumulative medication duration” is (30 x 3) + (60 x 2) = 210 days over the 10 month period.
Table 1 – High-Risk Medications at any dose or duration
|
Description |
Prescription |
|
Anticholinergics, first-generation antihistamines |
Brompheniramine Carbinoxamine Chlorpheniramine Clemastine Cyproheptadine Dexbrompheniramine Dexchlorpheniramine Dimenhydrinate Diphenhydramine (oral) Doxylamine Hydroxyzine Meclizine Orphenadrine Promethazine Pyrilamine Triprolidine |
|
Anticholinergics, anti-Parkinson agents |
Benztropine (oral) Trihexyphenidyl |
|
Antispasmodics |
Atropine (exclude ophthalmic) Belladonna alkaloids Chlordiazepoxide-clidinium Dicyclomide Hyoscyamine Methscopolamine Propantheline Scopolamine |
|
Antithrombotics |
Dipyridamole, oral short- acting |
|
Cardiovascular, alpha agonists, central |
Methyldopa Guanfacine |
|
Cardiovascular, other |
Disopyramide Nifedipine, immediate release |
|
Central nervous system, antidepressants |
Amitriptyline Clomipramine Amoxapine Desipramine Imipramine Trimipramine Nortriptyline Paroxetine Protriptyline |
|
Central nervous system, barbiturates |
Amobarbital Butabarbital Butalbital Pentobarbital Phenobarbital Secobarbital |
|
Central nervous system, vasodilators |
Ergot mesylates Isoxsuprine |
|
Central nervous system, other |
Meprobamate |
|
Endocrine system, estrogens with or without progestins; include only oral and topical patch products |
Conjugated estrogen Estropipate Estradiol Esterified estrogen |
|
Endocrine system, sulfonylureas, long- duration |
Chlorpropamide Glimepiride Glyburide |
|
Endocrine system, other |
Desiccated thyroid Megestrol |
|
Nonbenzodiazepine hypnotics |
Eszopiclon Zaleplon |
|
Pain medications, skeletal muscle relaxants |
Carisoprodol Chlorzoxazone Cyclobenzaprine Metaxalone Methocarbamol Orphenadrine |
|
Pain medications, other |
Indomethacin Meperidine Ketorolac, includes parentera |
*The registry version of the measure specifications only indicates the classes of drugs that are considered high-risk and do not include the specific coding of RxNorm. However, this measure aligns with the eCQM measure (CMS 156) and providers may review the RxNorm codes in the applicable eCQM value sets for submission.
Table 2 – High-Risk Medications With Days Supply Criteria
|
Description |
Prescription |
Days Supply Criteria |
|
Anti-Infectives, other |
Nitrofurantoin Nitrofurantoin macrocrystals Nitrofurantoin macrocrystals- monohydrate |
>90 days |
Numerator Instructions:
INVERSE MEASURE – A lower calculated performance rate for this measure indicates better clinical care or control. The “Performance Not Met” numerator option for this measure is the representation of the better clinical quality or control. Submitting that numerator option will produce a performance rate that trends closer to 0%, as quality increases. For inverse measures a rate of 100% means all of the denominator eligible patients did not receive the appropriate care or were not in proper control.
A high-risk medication is identified by either of the following:
• A prescription for medications classified as high risk at any dose and for any duration listed in Table 1
• Prescriptions for medications classified as high risk at any dose with greater than a 90 day cumulative medication duration listed in Table 2
Numerator Options:
Performance Met: At least two orders for high-risk medications from the same drug class (G9367)
OR
Performance Not Met: At least two orders for high-risk medications from the same drug class not ordered (G9368)
-OR-
NUMERATOR (SUBMISSION CRITERIA 2):
Patients with at least two orders of high-risk medications from the same drug class (i.e., antipsychotics and benzodiazepines), except for appropriate diagnoses.
Definitions:
The intent of the numerator is to assess if the patient has been ordered at least two high-risk medications from the same drug class (grouped by row) in Table 3 on different dates or service. The intent of the measure is to assess if the submitting provider ordered the high-risk medication(s). If the patient had a high-risk medication previously prescribed by another provider, they would not be counted towards the numerator unless the submitting provider also ordered a high-risk medication for them from the same drug class.
Index Prescription Start Date – the start date of the earliest prescription ordered for a high-risk medication during the measurement period.
Table 3 – High-Risk Medications
|
Description |
Prescription |
|
Antipsychotics, first (conventional) and second (atypical) generation |
• Aripiprazole |
|
Benzodiazepines, long, short and intermediate acting |
• Alprazolam |
*The registry version of the measure specifications only indicates the classes of drugs that are considered high-risk and do not include the specific coding of RxNorm. However, this measure aligns with the eCQM measure (CMS 156) and providers may review the RxNorm codes in the applicable eCQM value sets for submission.
Numerator Instructions:
INVERSE MEASURE – A lower calculated performance rate for this measure indicates better clinical care or control. The “Performance Not Met” numerator option for this measure is the representation of the better clinical quality or control. Submitting that numerator option will produce a performance rate that trends closer to 0%, as quality increases. For inverse measures a rate of 100% means all of the denominator eligible patients did not receive the appropriate care or were not in proper control.
A high-risk medication is identified by either of the following:
• A prescription for medications classified as high risk at any dose and for any duration listed in Table 3
Numerator Options:
Performance Met: At least two orders for high-risk medications from the same drug class (G9367)
OR
Performance Not Met: At least two orders for high-risk medications from the same drug class not ordered (G9368)
OR
Performance Not Met: Two or more antipsychotic prescriptions ordered for patients who had a diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder on or between January 1 of the year prior to the measurement period and the Index Prescription Start Date (IPSD) for antipsychotics (G0032)
OR
Performance Not Met: Two or more benzodiazepine prescriptions ordered for patients who had a diagnosis of seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, or severe generalized anxiety disorder on or between January 1 of the year prior to the measurement period and the IPSD for benzodiazepines (G0033)